News

Apobiologix News
All
News
Events

Apobiologix's Biosimilar Pegfilgrastim, Lapelga™ Approved in Canada

April 5, 2018

On April 5, Health Canada approved Apobiologix's pegfilgrastim biosimilar Lapelga. This marks the first pegfilgrastim biosimilar approved in Canada and the world.

Lapelga is a biosimilar of Amgen's Neulasta (pegfilgrastim). It is indicated in Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs.

Return to News & Events


Invention is not the only innovation.

Apobiologix logo

2400 North Commerce Parkway,
Suite 300,
Weston, Florida 33326

855-276-7744

Email